Firefly Neuroscience to Showcase AI-Powered Brain Health Solutions at October Investor Conferences

Firefly Neuroscience Gears Up for October Investor Conferences

Firefly Neuroscience, Inc. (NASDAQ: AIFF), an innovative AI company focused on improving brain health outcomes, has announced its participation in two significant investor conferences this October. The company, which specializes in developing solutions for patients with neurological and mental disorders, aims to showcase its groundbreaking technology to potential investors and industry professionals 1

1

2

Conference Details and Presentation Formats

The company will be participating in two distinct events:

1. Maxim Healthcare Virtual Summit (October 15-17, 2024):

   • Format: Fireside Chat with Maxim Analyst, Allen Klee
   • Date and Time: Thursday, October 17th at 10:00 a.m. ET
   • Webcast available on Firefly's investor relations website

2. ThinkEquity Conference (October 30, 2024):

   • Location: Mandarin Oriental Hotel, New York, NY
   • Presentation: Wednesday, October 30th at 11:00 a.m. ET
   • Webcast also available on the company's investor relations site

Investors interested in one-on-one meetings with Firefly's management can arrange them through their Maxim or ThinkEquity representatives, or by contacting KCSA Strategic Communications 2

2

Firefly's Innovative AI-Powered Technology

At the heart of Firefly's offerings is its FDA-510(k) cleared Brain Network Analytics (BNA™) technology. This AI-driven solution is revolutionizing the diagnosis and treatment monitoring of various neurological and mental health conditions, including depression, dementia, anxiety disorders, concussions, and ADHD 1

1

The BNA™ technology leverages artificial intelligence and machine learning, drawing insights from Firefly's extensive proprietary database. This database comprises standardized, high-definition longitudinal electroencephalograms (EEGs) from over 17,000 patients, representing twelve different disorders as well as clinically normal patients 2

2

Related Stories

Firefly Neuroscience to Showcase AI-Powered Brain Health Solutions at Florida Capital Event

Firefly Neuroscience Secures $12.4 Million Financing to Advance AI-Powered Brain Health Technology

Firefly Neuroscience's AI-Powered EEG Analytics Show Promise in Drug Development and Neuropsychiatric Care

Firefly Neuroscience Grants Inducement Shares to Executive Chairman, Highlighting AI-Driven Brain Health Solutions

Commercial Launch and Target Markets

Firefly is currently in the process of launching BNA™ commercially. The company is targeting two primary markets:

1. Pharmaceutical companies engaged in drug research and clinical trials
2. Medical practitioners for clinical use

When used in conjunction with an FDA-cleared EEG system, BNA™ provides clinicians with comprehensive insights into brain function. These insights can significantly enhance a clinician's ability to accurately diagnose mental and cognitive disorders and determine the most suitable therapy or drug to optimize patient outcomes 1

1

2

Firefly's Market Position and Future Prospects

As an AI company in the healthcare sector, Firefly Neuroscience is positioning itself at the intersection of technology and brain health. With its FDA clearance, patent protection, and a database built over 15 years, the company appears to be well-positioned to capitalize on the growing demand for innovative mental health solutions 1

1

The upcoming investor conferences present a significant opportunity for Firefly to showcase its technology and business model to potential investors and partners. As the company moves forward with its commercial launch, these events could play a crucial role in securing additional funding and partnerships to fuel its growth and market expansion 2

2